Q4 2022

Source filing unavailable

Q4 2022 · —

Revenue—

Net Income

-CA$22.58M

N/M vs Q4 2021

EPS, diluted—

Operating Cash Flow-CA$23,584,000N/M

Same quarter

Metric	Q4 2022	Q4 2021
Net Income	-CA$22.58M	-CA$17.29M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Medicenna Therapeutics Corp. · CIK 1807983 · Engraved from SEC EDGAR